EGFR and non-small cell lung carcinoma: In the phase III SINDAS trial (NCT02893332, N = 133), patients with EGFR-mutated synchronous OMD NSCLC treated with first-line TKI therapy were randomized to upfront LRT (using radiation therapy [RT]) versus no LRT.24